Blood Grouping Kit (ABO & Rh Typing — Anti-ABD Combipack)
Pack Sizes Available
Product Description
Technical Specifications
- Kit Contents and Antibody Class: Anti-A (blue coded, IgM monoclonal) + Anti-B (yellow coded, IgM monoclonal) + Anti-D (IgM or IgM+IgG blend depending on variant); all ready to use in calibrated dropper bottles; no dilution required
- Titre Specifications: Anti-A: ≥1:256 | Anti-B: ≥1:256 | Anti-D: ≥1:128 (confirmed from Tulip Diagnostics Eryscreen 3x10ml specification); suitable for slide and tube techniques; strong direct agglutination within 15-30 seconds on slide
- Test Method: Slide technique (2-minute procedure, direct agglutination read macroscopically) and tube technique (centrifuge 100-125 rcf, read agglutination on resuspension); no equipment required beyond glass slide, stick, and adequate lighting
- Storage and Shelf Life: Store at 2-8°C; do not freeze; shelf life 24-36 months from manufacture; return to refrigerator after use; confirm daily reactivity with known positive and negative red cell controls for each reagent
- Regulatory Status: CE-IVD marked (ISO 13485 compliant); CDSCO registered IVD (India); Tulip Diagnostics ISO certified manufacturer (Goa, India); for in vitro diagnostic use by trained blood bank personnel; handle blood-contact materials as potentially infectious
Frequently asked questions
The Blood Grouping Combipack contains three separate reagents — Anti-A, Anti-B, and Anti-D — that together determine a patient's complete ABO blood group and Rh(D) type. Anti-A detects the A antigen (positive result classifies patient as group A or AB). Anti-B detects the B antigen (positive result classifies patient as group B or AB). Together, they determine ABO type: A, B, AB, or O. Anti-D detects the D (Rh) antigen (positive result = Rh-positive; negative result = Rh-negative, subject to weak D testing for blood donors). The complete blood group is expressed as, for example, A Rh-positive or O Rh-negative.
The blood grouping combipack is confirmed available in: 3x5ml format (Anti-A 5ml + Anti-B 5ml + Anti-D 5ml — standard for smaller labs and district hospitals), 3x10ml format (standard institutional format for hospital blood banks and transfusion centres — confirmed as Tulip Diagnostics Eryscreen 3x10ml), and 24-test blister card kit (Tulip ABO Blood Grouping Kit, confirmed from PharmEasy listing). The Tulip Eryscreen Plus 3x10ml format contains Anti-A, Anti-B, and Anti-D IgM+IgG blend. All formats contain ready-to-use monoclonal IgM antibodies with calibrated dropper bottles.
As confirmed from the Tulip Diagnostics Eryscreen 3x10ml combipack specification published on microsidd.com: Anti-A minimum titre ≥1:256, Anti-B minimum titre ≥1:256, and Anti-D minimum titre ≥1:128. The lower Anti-D titre specification compared to Anti-A and Anti-B reflects the inherent difference in D antigen density on red cell membranes compared to ABO antigens, not a reduction in reagent quality. All three meet international blood grouping reagent standards for sensitivity and specificity.
The combipack format is preferred for several reasons: simplified procurement — one line item, one order, one invoice; matched lot numbers — all three reagents in the kit are from the same production batch, ensuring consistent performance characteristics within the test system; single expiry date — all three bottles share the same expiry, eliminating the risk of accidentally using an expired bottle from a mismatched individual order; storage efficiency — one box takes less refrigerator shelf space than three separately boxed items; and quality traceability — if any performance issue arises, a single lot number covers all three reagents.
The slide technique for ABO-D blood grouping takes approximately 2 to 3 minutes. On a clean glass slide, place one separate drop of Anti-A, Anti-B, and Anti-D in different labelled areas. Next to each reagent drop, place one drop of the patient's red cell suspension (2-5% concentration in saline). Mix each reagent-cell combination with a clean stick or mixing stick. Tilt the slide gently back and forth and observe for agglutination within 1 minute. Strong visible clumping is a positive result (antigen present). No clumping is a negative result. Read all three results together to classify the complete ABO-D blood group.
On each day of use, the reactivity of each reagent in the combipack must be confirmed by testing with known positive and negative red cell controls: Anti-A is tested against A1 cells (positive control) and O cells (negative control); Anti-B is tested against B cells (positive control) and O cells (negative control); Anti-D is tested against D-positive cells (positive control) and D-negative cells (negative control). All positive controls must produce strong agglutination and all negative controls must show no agglutination. If any control fails, that reagent batch must be quarantined and not used for patient testing until the issue is investigated.
Microlisa HIV Ag & Ab 4th Generation ELISA Test Kit
Blood screening exists in a category of laboratory work where the margin for error is not just professionally unacceptable but medically catastrophic. A false negative in HIV screening does not just fail a test. It compromises patient safety, undermines transfusion protocols, and exposes healthcare systems to risks that nobody wants to calculate. Microlisa HIV Ag & Ab 4th Generation ELISA was engineered to close the detection window that makes early HIV infection so difficult to identify reliably. This is an in-vitro qualitative enzyme immunoassay designed for simultaneous detection of antibodies to HIV-1 (including Group O and subtype C prevalent in India), HIV-2, and HIV-1 p24 antigen in human serum or plasma. The test is intended for screening of blood donors, diagnostic testing of individuals at risk for HIV infection, and clinical evaluation of patients with AIDS-related symptoms. It represents the fourth generation of HIV ELISA technology, which detects both antibodies and antigens simultaneously rather than antibodies alone. The clinical advantage of 4th generation testing is the shortened window period. Traditional antibody-only tests miss early seroconversion cases where HIV-1 p24 antigen is present but antibodies have not yet developed to detectable levels. By detecting p24 antigen during the acute infection phase (typically 2 to 4 weeks post-exposure), this assay identifies infections approximately 1 to 2 weeks earlier than 3rd generation antibody-only tests. That earlier detection matters critically in blood donor screening and post-exposure monitoring. The assay is based on sandwich ELISA methodology. Microtiter wells are pre-coated with HIV envelope proteins (gp41, C-terminus of gp120 for HIV-1, and gp36 for HIV-2) and anti-p24 monoclonal antibodies. When specimens are added, any HIV antibodies or p24 antigen present bind to the coated antigens or antibodies. After washing, horseradish peroxidase (HRPO) conjugated antigens and anti-p24 antibodies are added, forming a sandwich complex. The colorimetric reaction develops proportionally to the amount of HIV antibodies or antigen present, read at 450nm absorbance. The kit uses color-coded reagents to monitor procedural steps, reducing protocol errors during multi-step workflows. Breakaway microwell strips allow testing flexibility from single specimens to full 96-well plate runs. Storage stability is maintained at 2-8°C with a shelf life of 24 months unopened. Total assay time including incubation steps is approximately 120 minutes. Sensitivity and specificity meet international standards for 4th generation HIV screening. Clinical evaluations demonstrate 100% sensitivity in detecting seroconversion panels and p24 antigen standards quantified down to 200 pg/ml. Specificity exceeds 99.5% when tested against large sample populations. The test detects all major HIV-1 subtypes including Group O and subtype C, which are epidemiologically significant in the Indian subcontinent. For distributors supplying blood banks, transfusion centers, diagnostic laboratories, and public health screening programs, Microlisa HIV Ag & Ab represents a clinically validated 4th generation screening platform with predictable reorder cycles. Sara Wellness has been exporting in-vitro diagnostic kits and laboratory reagents from India for 15 years.
Advantage PAN Malaria Card Rapid Diagnostic Test Kit
Malaria diagnosis in endemic regions operates under time pressure that microscopy cannot always accommodate. A patient presenting with fever in a rural health center at midnight does not have the luxury of waiting until morning for a trained microscopist to arrive, prepare slides, and spend twenty minutes examining blood films under oil immersion. That delay can mean the difference between timely artemisinin treatment and cerebral malaria developing overnight. Advantage PAN Malaria Card was designed to deliver species-level diagnosis in settings where microscopy is impractical or unavailable. This is a rapid visual immunoassay for qualitative detection of all four human Plasmodium species (P. falciparum, P. vivax, P. malariae, P. ovale) based on pan-specific plasmodium lactate dehydrogenase (pLDH) antigen in whole blood. The test provides results within 20 minutes using a simple fingerstick blood sample, no laboratory equipment required, making it ideal for point-of-care testing in primary health centers, rural clinics, field hospitals, and outbreak response settings. The assay is based on sandwich immunochromatography using monoclonal antibodies specific to pLDH, an enzyme produced by all Plasmodium species during their erythrocytic life cycle. When infected blood is added to the test device and assay buffer is applied, red blood cells lyse and pLDH antigen (if present) binds to gold-conjugated anti-pLDH antibodies. This complex migrates along the nitrocellulose membrane and is captured by immobilized anti-pLDH antibodies at the test line, producing a visible pink-purple band that confirms malaria infection. The see-through device design allows direct visualization of sample migration and result development, which helps identify invalid tests caused by insufficient sample volume or improper application. This transparency reduces the ambiguity that plagues some lateral flow devices where internal workings are hidden. Sensitivity and specificity have been validated through WHO malaria RDT evaluation programs using panels of wild and cultured parasites. The test detects parasitemia levels above 100 parasites per microliter of blood for both P. falciparum and P. vivax, which is clinically relevant for symptomatic infections requiring treatment. Specificity exceeds 99% when tested against cross-reactive conditions including dengue, leptospirosis, typhoid, and other febrile illnesses common in malaria-endemic areas. Shelf life is 24 to 30 months when stored at 4-30°C, which is critical for stockpiling in tropical climates where cold chain infrastructure is unreliable. The extended temperature stability means the test remains functional even when stored at ambient temperatures in resource-limited settings. Each kit contains individually sealed test devices, buffer vials, blood collection pipettes, and instructions for use. The test requires no special training beyond basic clinical skills and can be performed by nurses, paramedics, or trained community health workers. For distributors supplying national malaria control programs, public health departments, NGO field operations, and private diagnostic laboratories, Advantage PAN Malaria Card represents a WHO-evaluated rapid diagnostic platform with predictable consumption tied to malaria case loads. Sara Wellness has been exporting rapid diagnostic test kits and laboratory reagents from India for 15 years.
Human Serum Coombs Antisera (Antihuman Globulin Reagent)
Blood banking operates on a fundamental requirement that most people never think about until something goes wrong. Every unit of blood transfused must be confirmed compatible with the recipient's immune system. Every pregnant woman screened for antibodies that could harm her unborn child. Every suspected case of hemolytic anemia investigated for antibodies attacking the patient's own red blood cells. None of this happens without Coombs antisera making the invisible antibodies visible. Human Serum Coombs Antisera is the reagent that makes antiglobulin testing possible in blood banks and immunohematology laboratories worldwide. This is antihuman globulin (AHG) reagent used in both direct and indirect antiglobulin tests (Coombs tests) to detect antibodies and complement components bound to red blood cell surfaces or present free in serum. The reagent is produced by immunizing animals (typically rabbits) with human immunoglobulins, which induces production of polyclonal antibodies specific for human IgG antibodies and complement factor C3d. When added to washed red blood cells coated with IgG or complement, the antihuman antibodies bind to the human antibodies and form bridges between adjacent sensitized cells, causing visible agglutination. The direct antiglobulin test (DAT) detects antibodies or complement already bound to red blood cell surfaces in vivo. This test is critical for diagnosing autoimmune hemolytic anemia, investigating hemolytic transfusion reactions, and diagnosing hemolytic disease of the fetus and newborn. The indirect antiglobulin test (IAT) detects free antibodies circulating in serum or plasma. This test is essential for pre-transfusion antibody screening, crossmatching blood units for compatibility, and prenatal antibody screening in pregnant women. Polyspecific Coombs antisera (like the green-colored reagent shown) contains antibodies against both IgG and C3d complement, providing broad-spectrum detection. When the polyspecific reagent produces a positive result, monospecific antisera (anti-IgG alone or anti-C3d alone) are used for follow-up testing to characterize whether red cells are coated with IgG antibodies, complement, or both. This differentiation is clinically important because it helps determine the cause and clinical significance of the positive test. The reagent is typically dyed green using patent blue and tartrazine to allow easy visual identification during laboratory workflows where multiple reagents are used simultaneously. Storage at 2-8°C maintains reagent potency until the expiration date printed on the bottle, typically 18 to 24 months from manufacture. The reagent contains sodium azide (0.1% w/v) as a preservative, which inhibits bacterial growth but requires careful handling and disposal. Each dropper bottle delivers approximately 40 microliters per drop, allowing precise volumetric dosing during testing. The reagent must not be diluted and should not be used if turbid, as turbidity indicates bacterial contamination or protein aggregation that will compromise test performance. For distributors supplying blood banks, hospital transfusion services, reference immunohematology laboratories, and donor screening centers, Coombs antisera represents an essential reagent with consumption directly tied to transfusion volume and prenatal screening programs. Sara Wellness has been exporting immunohematology reagents and blood banking supplies from India for 15 years.